World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
101
Citations
50495
World Ranking
7835
National Ranking
4082

Oliver Sartor publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Oliver Sartor sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,192 publications — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Oliver Sartor D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Oliver Sartor sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 101 D-Index — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Oliver Sartor is affiliated with Tulane University in the United States and has a significant research presence in the field of Medicine, with a particular focus on Oncology and Cancer Research. Their scholarly contributions include substantial work related to prostate cancer diagnosis, treatment, and radiopharmaceutical applications.

Their research encompasses a variety of subfields within Medicine, notably:

  • Pulmonary and Respiratory Medicine
  • Radiology, Nuclear Medicine and Imaging
  • Oncology
  • Cancer Research
  • Molecular Biology

Sartor's main areas of research focus on topics such as:

  • Prostate Cancer Treatment and Research
  • Radiopharmaceutical Chemistry and Applications
  • Prostate Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • PARP inhibition in cancer therapy
  • Cancer Immunotherapy and Biomarkers
  • Cancer, Lipids, and Metabolism

Their frequently published work appears in several prominent journals, including:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Urology
  • International Journal of Radiation Oncology*Biology*Physics
  • Journal of Nuclear Medicine

Notable recent papers authored by Oliver Sartor include:

  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (2021, New England Journal of Medicine)
  • Olaparib for Metastatic Castration-Resistant Prostate Cancer (2020, New England Journal of Medicine)
  • Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer (2020, New England Journal of Medicine)
  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 (2020, European Urology)
  • Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019 (2020, Journal of Clinical Oncology)

Oliver Sartor frequently collaborates with other researchers, with frequent co-authors including:

  • Pedro C. Barata
  • Elisa M. Ledet
  • Karim Fizazi
  • Johann S. de Bono
  • Ellen Jaeger

Best Publications

  • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

    Johann Sebastian De Bono;Stephane Oudard;Mustafa Ozguroglu;Steinbjørn Hansen

  • Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

    C. Parker;S. Nilsson;S. Nilsson;D. Heinrich;S. I. Helle

  • Olaparib for metastatic castration-resistant prostate cancer

    Johann de Bono;Joaquin Mateo;Karim Fizazi;Fred Saad

  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

    Oliver Sartor;Johann de Bono;Kim N Chi;Karim Fizazi

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

    Glenn J. Bubley;Michael Carducci;William Dahut;Nancy Dawson

  • Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

    Kenneth R. Carson;Andrew M. Evens;Elizabeth A. Richey;Thomas M. Habermann

  • Prostate Specific Antigen Best Practice Statement: 2009 Update

    Kirsten L. Greene;Peter C. Albertsen;Richard J. Babaian;H. Ballentine Carter

  • Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

    William U. Shipley;Wendy Seiferheld;Himanshu R. Lukka;Pierre P. Major

  • Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

    Oliver Sartor;Robert E Coleman;Sten Nilsson;Daniel Heinrich

  • Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

    Maha Hussain;Joaquin Mateo;Karim Fizazi;Fred Saad

  • A review of technology and policy deep decarbonization pathway options for making energy-intensive industry production consistent with the Paris Agreement

    Chris Bataille;Max Åhman;Karsten Neuhoff;Lars J. Nilsson

  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran

  • Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer.

    C L Bennett;M R Ferreira;T C Davis;J Kaplan

  • Metastatic Prostate Cancer

    Oliver Sartor;Johann S. de Bono

  • Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

    Peter Hoskin;Oliver Sartor;Joe M O'Sullivan;Dag Clement Johannessen

  • Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

    Thomas Powles;Thomas Powles;Tibor Csőszi;Mustafa Özgüroğlu;Nobuaki Matsubara

  • Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy : the SPARC trial

    Cora N. Sternberg;Daniel P. Petrylak;Oliver Sartor;J. Alfred Witjes

  • Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guideline

    Ian M. Thompson;Ian M. Thompson;Richard K. Valicenti;Richard K. Valicenti;Peter Albertsen;Peter Albertsen;Brian J. Davis;Brian J. Davis

  • Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.

    Oliver Sartor;Robert H Reid;Peter J Hoskin;Donald P Quick

Frequent Co-Authors

Chris Parker
Chris Parker Institute of Cancer Research
Celestia S. Higano
Celestia S. Higano University of Washington
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
Neal D. Shore
Neal D. Shore Carolina Urologic Research Center
Charles L. Bennett
Charles L. Bennett Johns Hopkins University
Cora N. Sternberg
Cora N. Sternberg Cornell University
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Susan Halabi
Susan Halabi Duke University
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Robert E. Coleman
Robert E. Coleman University of Sheffield

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in a career in medicine but seeking flexible or alternative routes, online healthcare degrees offer a range of options. online adn programs for non nurses make it possible for those without nursing backgrounds to begin their journey toward becoming a registered nurse from the comfort of home.

If you’re interested in the administrative or technical side of healthcare, consider enrolling in one of the best online medical billing and coding schools. These programs teach essential skills needed for managing medical records, insurance claims, and coding—all key roles in any modern healthcare setting.

Some students may be concerned about challenging entry exams. Fortunately, there are nursing schools that don't require teas, making applications less stressful while maintaining quality education standards.

Finally, aspiring healthcare managers can fast-track their careers with accelerated healthcare administration degree online programs. These pathways prepare graduates to work in leadership and operations roles within hospitals, clinics, and wider healthcare systems.

Best Scientists Citing Oliver Sartor

Trending Scientists

Recently Published Articles